What are the potential renal risks associated with long‑term use of polyethylene glycol (PEG)?

Renal Risks of Long-Term PEG Use

Long-term PEG use carries minimal renal risk in patients with normal kidney function, but should be avoided or used only under physician supervision in patients with pre-existing kidney disease 1.

Key Safety Considerations

FDA Warning for Kidney Disease

The FDA drug label explicitly states: "DO NOT USE if you have kidney disease, except under the advice and supervision of a doctor" 1. This is the most critical contraindication to understand when prescribing PEG.

Evidence from Clinical Guidelines

The 2023 AGA-ACG guidelines on chronic idiopathic constipation provide strong support for PEG use, with a strong recommendation for PEG in adults with chronic constipation based on moderate certainty evidence 2. Importantly, these guidelines note:

• Response to PEG has been shown to be durable over 6 months 2
• Side effects are primarily gastrointestinal: abdominal distension, loose stool, flatulence, and nausea 2
• No conclusive evidence of serious adverse events emerged from randomized trials 2

The guidelines reviewed three major randomized controlled trials (total n=429 patients) with treatment durations up to 6 months, and found that serious adverse events were very rare, with no definitive pattern suggesting renal toxicity 2.

Real-World Renal Risk Data

Acute Kidney Injury Risk

While PEG is generally safe, population-based and observational studies have identified specific scenarios where renal injury can occur:

Colonoscopy preparation context:

• A prospective study of 1,163 patients found acute renal dysfunction in 2.2% and acute kidney injury in 0.5% after PEG use for colonoscopy 3
• All patients with renal injury recovered fully 3
• NSAID use before colonoscopy significantly increased AKI risk (odds ratio 6.5) 3

Population-based findings:

• A Korean case-crossover study found PEG use associated with increased ARF risk (adjusted OR 2.1-3.1 depending on time window) 4
• However, this study examined colonoscopy preparation (acute, high-volume use) rather than chronic daily dosing

Mechanism of Potential Renal Effects

Animal studies suggest that very high doses of PEG may cause:

• Osmotic effects in urine leading to increased kidney weights 5
• Possible slight, reversible renal toxicity at doses of 2.5-5.0 ml/kg/day in rats 5
• No microscopic kidney changes were observed even at these high doses 5

Clinical Algorithm for Safe PEG Use

Before initiating long-term PEG:

1. Screen for kidney disease - Check baseline creatinine/eGFR

   • If eGFR <30 mL/min: Do not use without nephrology consultation 1
   • If eGFR 30-60 mL/min: Use with caution and monitoring

2. Assess concurrent medications

   • Avoid NSAIDs when possible - significantly increases AKI risk 3
   • Review other nephrotoxic medications (aminoglycosides, vancomycin, ACE inhibitors)

3. Ensure adequate hydration

   • PEG should be mixed with 8 ounces of liquid 2
   • Patients should maintain adequate fluid intake throughout the day 4

During long-term use:

• Monitor renal function periodically (every 6-12 months) in patients with risk factors
• Watch for signs of dehydration, especially in elderly patients
• Educate patients about proper dosing - misuse/overdose can cause severe complications 6

Important Caveats

Distinguish between different PEG exposures:

• Oral PEG 3350 for constipation (17g daily) has excellent safety profile 2
• High-dose PEG for colonoscopy prep represents acute, massive exposure with different risk profile 3, 4
• Intravenous PEG (in drug formulations like lorazepam) carries distinct nephrotoxicity risk 7, 8

Extreme misuse scenarios:

• Case reports of acute renal failure exist, but involve profound overdose (far exceeding recommended doses) 6
• These represent aberrant use patterns, not therapeutic dosing

Bottom Line for Clinical Practice

For patients with normal renal function, long-term daily PEG use (17g) is safe and well-tolerated 2. The primary concerns are gastrointestinal side effects, not nephrotoxicity. However, absolute avoidance in established kidney disease 1 and caution with concurrent NSAIDs 3 are essential safety measures. The theoretical renal risks identified in population studies likely reflect dehydration and acute high-volume exposure rather than chronic therapeutic dosing.